Technology evaluation: TNFerade, GenVec.
TNFerade is a new gene therapy drug under development by GenVec that employs a replication-deficient adenovector carrying the gene for human tumor necrosis factor (TNF)-alpha, regulated by a radiation-sensitive promoter. TNFerade is currently undergoing phase II trials for the potential treatment of cancer.
D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000494:pharmacology; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D013678:Technology, Pharmaceutical / Q000379:methods*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000494:pharmacology
D015507:Drugs, Investigational; D014409:Tumor Necrosis Factor-alpha